Rocket Pharmaceuticals (RCKT) announced that it intends to offer and sell $150M of shares of its common stock in an underwritten public offering. Morgan Stanley, Leerink Partners and Cantor are acting as joint book-running managers for the offering, and LifeSci Capital is acting as lead manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals Advances Genetic Therapies Pipeline
- Rocket Pharmaceuticals Advances Danon Disease and PKD Studies
- Rocket Pharmaceuticals has not initiated enrollment in Phase 2 RP-L301 study
- Rocket Pharmaceuticals announces publication of Phase 1 RP-A501 long-term data
- Rocket Pharmaceuticals price target raised to $51 from $50 at Scotiabank